Drug delivery systems for the topical treatment of cutaneous leishmaniasis

Bibliography

• Sacks DL. Metacyclogenesis in Leishmania promastigotes. Exp Parasitol 1989;69:100-3
   PubMed Web of Science ®Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011;9:604-15
   PubMed Web of Science ®Google Scholar
• Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis 2008;21:483-8
   PubMed Web of Science ®Google Scholar
• Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989;41:687-725
   PubMed Web of Science ®Google Scholar
• Berman J. Visceral leishmaniasis in the New World & Africa. Indian J Med Res 2006;123:289-94
   PubMed Web of Science ®Google Scholar
• Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002;3:538-44
   PubMedGoogle Scholar
• Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005;14:1337-46
   PubMed Web of Science ®Google Scholar
• Soto JM, Toledo JT, Gutierrez P, Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51
   PubMed Web of Science ®Google Scholar
• Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003;16:397-401
   PubMed Web of Science ®Google Scholar
• Armijos RX, Weigel MM, Calpovina M, Comparison of the effectiveness of two topical paromomycin treatment versus meglumine antimoniate for new world cutaneous leishmaniasis. Acta Trop 2004;91:153-60
   PubMed Web of Science ®Google Scholar
• Santos AM, Noronha EF, Ferreira LA, Efeito de uma formulacao hidrofilica de paromomicina topica na leishmaniose cutanea em pacientes com contra-indicacoes de tratamento com antimonial pentavalente. Rev Soc Bras Med Trop 2008;41:444-8
   PubMed Web of Science ®Google Scholar
• Ben-Salah A, Buffet PA, Morizot G, WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double Blind, placebo controlled study. Plos Negl Trop Dis 2009;3:432
   Web of Science ®Google Scholar
• Neal RA, Murphy AG, Olliaro P, Croft SL. Aminosidine ointments for the treatment of experimental cutaneous. Trans R Soc Trop Med Hyg 1994;88:223-35
   PubMed Web of Science ®Google Scholar
• Asilian A, Jalayer T, Whitworth JAG, A randomized placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995;53:648-51
   PubMed Web of Science ®Google Scholar
• Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14
   PubMed Web of Science ®Google Scholar
• Papakostas D, Rancan F, Sterry W, Nanoparticles in dermatology. Arch Dermatol Res 2011;303:533-50
   PubMed Web of Science ®Google Scholar
• Pierre MBR, Costa ISM. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 2011;303:607-21
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Barry BW, William SD. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 2008;34:203-22
   PubMed Web of Science ®Google Scholar
• Carneiro G, Santos DCM, Oliveira MC, Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2010;20:16-23
   PubMed Web of Science ®Google Scholar
• Chiang B, Essick E, Ehringer W, Enhancing skin wound healing by direct delivery of intracellular adenosine triphosphate. Am J Surg 2007;193:213-18
   PubMed Web of Science ®Google Scholar
• Lee JP, Jalili RB, Tredget EE, Antifibrogenic effects of liposome-encapsulated IFN-2b cream on skin wounds in a fibrotic rabbit ear model. J Interf Cytok Res 2005;25:627-31
   PubMed Web of Science ®Google Scholar
• Langer S, Botteck NM, Bosse B, Effect of polyvinylpyrrolidone-iodine liposomal hydrogel on wound microcirculation in SKH1-hr hairless mice. Eur Surg Res 2006;38:27-34
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 2008;17:787-94
   PubMed Web of Science ®Google Scholar
• Fernandez MM, Malchiode EL, Algranati ID. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 2011;55:86-93
   PubMed Web of Science ®Google Scholar
• Kanyok TP, Killian AD, Rodvold KA, Danziger LH. Pharmacokinetics of intramusculary administered aminosidine in healthy subjects. Antimicrob Agents Chemother 1997;41:982-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81
   PubMed Web of Science ®Google Scholar
• Aguiar MG, Silva D, Nunan FA, Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. J Antimicrob Chemother 2009;64:1234-40
   PubMed Web of Science ®Google Scholar
• Paris C, Louseau P, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004;48:852-9
   PubMed Web of Science ®Google Scholar
• Croft SL, Engel J. Miltefosine – discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc of Trop Med Hyg 2006;100(Suppl 1):1-4
   Google Scholar
• Rakotomanga M, Blanc S, Gaudin K, Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1425-30
   PubMed Web of Science ®Google Scholar
• Wadhone P, Maiti M, Agarwal R, Miltefosine promotes IFN-gamma-dominated antileishmanial immune response. J Immunol 2009;182:7146-54
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Gutierrez P, Treatment of american cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001;33:E57-61
   PubMedGoogle Scholar
• Kaminsky R. Miltefosine zentaris. Current Opin Investig Drugs 2002;3:550-4
   PubMedGoogle Scholar
• Berman J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug and Metab Toxicol 2008;4:1209-12
   PubMed Web of Science ®Google Scholar
• Golenser J, Frakenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental leishmaniasis with amphotericin B-Arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 1999;43:2209-14
   PubMed Web of Science ®Google Scholar
• Baginski M, Czub J. Amphotericin B and. Its New Derivatives – Mode of Action. Curr Drug Metab 2009;10:459-69
   PubMed Web of Science ®Google Scholar
• Croft S, Olliaro P. Leishmaniasis chemotherapy: challenges and opportunities. Clin Microbiol Infect 2011;17:1478-83
   PubMed Web of Science ®Google Scholar
• Cohen BE. Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 1998;162:95-106
   Web of Science ®Google Scholar
• Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine 2006;1:417-32
   PubMed Web of Science ®Google Scholar
• Erbagci Z, Tuncel AA, Erkilic S, Zer Y. Successful treatment of antifungal- and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream. Mycopathologia 2005;159:521-6
   PubMed Web of Science ®Google Scholar
• Arevalo I, Ward B, Miller R, Successful treatment of drug-resistant cutaneous Leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51
   PubMed Web of Science ®Google Scholar
• El-On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Exp Parasitol 2007;116:156-62
   PubMed Web of Science ®Google Scholar
• Slade HB, Owens ML, Tomai MA, Miller RJ. Imiquimod 5% cream (Aldara™). Exp Opin Invest Drugs 1998;7:437-49
   PubMedGoogle Scholar
• Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149:5-8
   PubMed Web of Science ®Google Scholar
• Ganier T, Mantyla A, Jarvinen T, In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007;60:802-10
   PubMed Web of Science ®Google Scholar
• Seifert K. Structures, targets and recent approaches in antileishmanial drug discovery and development. Open Med Chem J 2011;5:31-9
   PubMedGoogle Scholar
• Moser K, Kriwet K, Naik A, Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001;52:103-12
   PubMed Web of Science ®Google Scholar
• Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 2008;17:1063-72
   PubMed Web of Science ®Google Scholar
• Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 2006;3:211-24
   PubMedGoogle Scholar
• Trommer H, Neubert RH. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol 2006;19:106-21
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H, Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96
   PubMed Web of Science ®Google Scholar
• Neuber H. Leishmaniasis. J Dtsch Dermatol Ges 2008;6:754-652
   PubMed Web of Science ®Google Scholar
• Gattu S, Maibach HI. Enhanced absorption through damaged skin: an overview of the in vitro human model. skin. Pharmacol Physiol 2010;23:171-6
   Web of Science ®Google Scholar
• Markle WH, Makhoul K. Cutaneous Leishmaniasis: recognition and Treatment. Am Fam Physican 2004;69:1455-60
   PubMed Web of Science ®Google Scholar
• El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984;26:745-51
   PubMed Web of Science ®Google Scholar
• El-On J, Jacobs GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988;4:76-81
   PubMedGoogle Scholar
• Carter KC, Alexander J, Baille AJ. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin. Ann Trop Med Parasitol 1989;88:233-9
   Google Scholar
• Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin. J Parasitol 1999;85:354-9
   PubMed Web of Science ®Google Scholar
• El-On J, Livshin R, Even-Paz Z, Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87:1110-86
   Web of Science ®Google Scholar
• Soto J, Hernandez N, Mejia H, Successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimoniate. Clin Infect Dis 1995;20:47-51
   PubMed Web of Science ®Google Scholar
• Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/methylbenzetonium chloride plus parenteral meglumine antimoniate as treatment for american cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998;26:56-8
   PubMed Web of Science ®Google Scholar
• Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hig 2001;65:466-70
   PubMed Web of Science ®Google Scholar
• Bryceson ADM, Murphy A, Moody AH. Treatment of “Old World” cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994;88:226-8
   PubMed Web of Science ®Google Scholar
• Ben-Salah A, Zakraoui H, Zaatour A, A randomized placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6
   PubMed Web of Science ®Google Scholar
• Asilian A, Jalayer T, Nilforoohzadeh M, Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003;81:353-9
   PubMed Web of Science ®Google Scholar
• Castro GA, Nascimento DS, Nunan EA, In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin. S. T. P. Pharm Sci 2003;13:203-8
   Web of Science ®Google Scholar
• Simon GA, Maibach HI. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations – an overview. Skin Pharmacol Appl skin Physiol 2000;13:229-34
   PubMedGoogle Scholar
• Jacobi U, Kaiser M, Toll R, Porcine ear skin: an in vitro model for human skin. Skin Res Technol 2007;13:19-24
   PubMed Web of Science ®Google Scholar
• Walker M, Hulme TA, Rippon MG, In Vitro models for the percutaneous delivery of active tissue repair agents. J Pharm Sci 1997;86:1379-84
   PubMed Web of Science ®Google Scholar
• Grevelink AS, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996;34:257-72
   PubMed Web of Science ®Google Scholar
• Lalor CB, Flynn GL, Weiner N. Formulation factors affecting release of drug from topical formulations. II. Effect of solubility on in vitro delivery of a series of n-alkyl p-aminobenzoates. J Pharm Sci 1995;84:673-6
   PubMed Web of Science ®Google Scholar
• Goncalves GS, Fernandes AP, Souza RCC, Activity of a paromomycin hydrophilic formulation for tropical treatment of infections by Leishmania (Leshmania) amazonensis and Leishmania (Vianna) braziliensis. Acta Trop 2005;93:161-7
   PubMed Web of Science ®Google Scholar
• Mussi SV, Fernandes AP, Ferreira LA. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res 2007;100:1221-6
   PubMed Web of Science ®Google Scholar
• Aguiar MG, Pereira AM, Fernandes AP, Ferreira LA. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrob Agents Chemother 2010;54:4699-704
   PubMed Web of Science ®Google Scholar
• Coderch L, Fonollosa J, De Pera M, Influence of cholesterol on liposome fluidity by EPR. Relationship with percutaneous absorption. J Control Release 2000;68:85-95
   PubMed Web of Science ®Google Scholar
• Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002;54(Suppl 1):S41-55
   PubMed Web of Science ®Google Scholar
• Kim MK, Chung SJ, Lee MH, Targeted and sustained delivery of hydrocortisone to normal stratum corneum-removed skin without enhanced skin absorption using a liposome gel. J Control Release 1997;46:243-51
   Web of Science ®Google Scholar
• Mohebali M, Fotouhi A, Hoosmand B, Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007;103:33-40
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M, Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-11
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999;93:85-90
   PubMed Web of Science ®Google Scholar
• Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators Imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999;179:1485-94
   PubMed Web of Science ®Google Scholar
• Arevalo I, Tulliano G, Quispe A, Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44:1549-54
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Alshiltawy M, El Khalawany M, Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int J Dermatol 2009;48:862-9
   PubMed Web of Science ®Google Scholar
• Miranda-Verastegui C, Tulliano G, Gyorkos TW, First-Line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009;3:e491
   PubMed Web of Science ®Google Scholar
• Meymandi SS, Javadi A, Dabiri S, Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Arch Iran Med 2011;14:238-43
   PubMed Web of Science ®Google Scholar
• Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003;42:576-9
   PubMed Web of Science ®Google Scholar
• Mantyla A, Garnier T, Rautio J, Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 2004;47:188-95
   PubMed Web of Science ®Google Scholar
• Garnier T, Mantyla A, Jarvinen T, Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol 2007;59:41-9
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4:297-305
   PubMedGoogle Scholar
• Wu X, Landfester K, Musyanovych A, Guy RH. Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-23
   PubMed Web of Science ®Google Scholar
• Solans C, Izquierdo P, Nolla J, Nano-emulsions. Curr Opin Coll Int Science 2005;10:102-10
   Web of Science ®Google Scholar
• Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004;30:289-96
   PubMed Web of Science ®Google Scholar
• Jaafari MR, Bavarsad N, Bazzaz BSF, Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009;53:2259-65
   PubMed Web of Science ®Google Scholar
• Egito EST, Araujo IB, Damasceno BPGL, Price JC. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity. J Pharm Sci 2002;91:2354-66
   PubMed Web of Science ®Google Scholar
• Frankeburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother 1998;42:3092-6
   PubMed Web of Science ®Google Scholar
• Vardy D, Barenholz Y, Naftoliev N, Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 2001;95:184-6
   PubMed Web of Science ®Google Scholar
• Zvulunov A, Cagnano E, Frankenburg S, Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin. B. Pediatr Infect Dis J 2003;22:567-9
   PubMed Web of Science ®Google Scholar
• Santos CM, Oliveira RB, Arantes VT, Amphotericin B-loaded Nanocarriers for Topical Treatment of Cutaneous Leishmaniasis: Development, Characterization, and In Vitro Skin Permeation Studies. J Biomed Nanotechnol 2012;8:322-9. Copyright © American Scientific Publishers.
   PubMed Web of Science ®Google Scholar
• The United Pharmacopeia; the national formulary - USP 31. United States Pharmacopeial convention, Rockville; 2008
   Google Scholar
• British Pharmacopeia. Her Majesty's Stationary Office, London; 2005
   Google Scholar